Management of immune thrombocytopenia: Korean experts recommendation in 2017

on the behalf of Korean Aplastic Anemia Working Party

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Management options for patients with immune thrombocytopenia (ITP) have evolved substantially over the past decades. The American Society of Hematology published a treatment guideline for clinicians referring to the management of ITP in 2011. This evidence- based practice guideline for ITP enables the appropriate treatment of a larger proportion of patients and the maintenance of normal platelet counts. Korean authority operates a unified mandatory national health insurance system. Even though we have a uniform standard guideline enforced by insurance reimbursement, there are several unsolved issues in real practice in ITP treatment. To optimize the management of Korean ITP patients, the Korean Society of Hematology Aplastic Anemia Working Party (KSHAAWP) reviewed the consensus and the Korean data on the clinical practices of ITP therapy. Here, we report a Korean expert recommendation guide for the management of ITP.

Original languageEnglish
Pages (from-to)254-263
Number of pages10
JournalBlood Research
Issue number4
StatePublished - 2017

Bibliographical note

Publisher Copyright:
© 2017 Korean Society of Hematology.


  • Aplastic Anemia Working Party
  • ITP
  • Management
  • Recommendation


Dive into the research topics of 'Management of immune thrombocytopenia: Korean experts recommendation in 2017'. Together they form a unique fingerprint.

Cite this